Search

Your search keyword '"Reix, P."' showing total 361 results
Start Over Author "Reix, P." Publication Year Range Last 10 years
361 results on '"Reix, P."'

1. Development of MKIDs in the Optical and Near-infrared Bands for SPIAKID

Author

Hu, Jie, Nicaise, Paul, Boussaha, Faouzi, Martin, Jean-Marc, Chaumont, Christine, Marret, Alexine, Reix, Florent, Firminy, Josiane, Vacelet, Thibaut, Pham, Viet Dung, Piat, Michel, Caffau, Elisabetta, and Bonifacio, Piercarlo

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

SpectroPhotometric Imaging in Astronomy with Kinetic Inductance Detectors (SPIAKID) aims at designing, building, and deploying on the sky a spectrophotometric imager based on microwave kinetic inductance detectors (MKIDs) in the optical and near-infrared bands. MKIDs show a fast response and the ability to resolve photon energy compared to the conventional Charge-coupled Devices (CCDs). In this paper, we present the design and simulation of the MKID arrays for SPIAKID. The detectors consist of four arrays with each array of 20,000 lumped-element pixels, and each array will be read with 10 readout lines. %The array is designed to have resonances between 4-8GHz with a frequency spacing of 2 MHz and a coupling quality factor (Qc) of about 50000. The meander material of the resonators is trilayer TiN/Ti/TiN to have better uniformity of the critical temperature across the array. We also present the measurement result for a test array with $30\times30$ pixels which is a subset of the designed 2000-pixel array to verify the design and fabrication. The current measured best energy resolving power $R = E/\Delta E$ is 2.4 at $\lambda = 405~$nm and the current medium R is around 1.7. We have also observed the response of the TiN/Ti/TiN is much smaller than expected., Comment: 9 pages, 6 figures. Accepted by the Journal of Low Temperature Physics

Published
2023

2. Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy

Author

Bouazza, Naïm, Urien, Saïk, Foissac, Frantz, Choupeaux, Laure, Lui, Gabrielle, Froelicher Bournaud, Léo, Rouillon, Steeve, Zheng, Yi, Bardin, Emmanuelle, Stremler, Nathalie, Bessaci, Katia, Bihouee, Tiphaine, Coirier-Duet, Emmanuelle, Marguet, Christophe, Deneuville, Eric, Laurans, Muriel, Reix, Philippe, Gerardin, Michèle, Mittaine, Marie, Epaud, Ralph, Thumerelle, Caroline, Weiss, Laurence, Berthaud, Romain, Semeraro, Michaela, Treluyer, Jean-Marc, Benaboud, Sihem, and Sermet-Gaudelus, Isabelle

Published
2024
Full Text
View/download PDF

6. Long-term evolution of neuroendocrine cell hyperplasia of infancy: the FRENCHI findings

Author

Dervaux, Morgane, Thumerelle, Caroline, Fabre, Candice, Abou-Taam, Rola, Bihouee, Tiphaine, Brouard, Jacques, Clement, Annick, Delacourt, Christophe, Delestrain, Céline, Epaud, Ralph, Ghdifan, Sofiane, Hadchouel, Alice, Houdouin, Véronique, Labouret, Géraldine, Perisson, Caroline, Reix, Philippe, Renoux, Marie-Catherine, Troussier, Françoise, Weiss, Laurence, Mazenq, Julie, Nathan, Nadia, and Dubus, Jean-Christophe

Published
2023
Full Text
View/download PDF

7. Design of Near Infrared and Visible Kinetic Inductance Detectors Using MIM Capacitors

Author

Beldi, S., Boussaha, F., Chaumont, C., Mignot, S., Reix, F., Tartari, A., Vacelet, T., Traini, A., Piat, M., and Bonifacio, P.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Physics - Applied Physics, Physics - Instrumentation and Detectors
Abstract

We are developing superconducting Microwave Kinetic Inductance Detectors to operate at near infrared and optical wavelengths for astronomy. In order to efficiently meet with the requirements of astronomical applications, we propose to replace the interdigitated capacitor by a metal, insulator, metal capacitor which has the advantage of presenting a larger capacitance value within a much smaller space. The pixel will occupy a space of typically 100 micrometers by 85 micrometers which is nine times less than a typical pixel size using the interdigitated capacitor operating at the same frequency, below 2 GHz.

Published
2019

8. French national cohort of neuroendocrine cell hyperplasia of infancy (FRENCHI) study: diagnosis and initial management

Author

Fabre, Candice, Thumerelle, Caroline, Dervaux, Morgane, Abou-Taam, Rola, Bihouee, Tiphaine, Brouard, Jacques, Clement, Annick, Delacourt, Christophe, Delestrain, Céline, Epaud, Ralph, Ghdifan, Sofiane, Hadchouel, Alice, Houdouin, Véronique, Labouret, Géraldine, Perisson, Caroline, Reix, Philippe, Renoux, Marie-Catherine, Troussier, Françoise, Weiss, Laurence, Mazenq, Julie, Nathan, Nadia, and Dubus, Jean-Christophe

Published
2022
Full Text
View/download PDF

9. Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge

Author

Mornex, J.-F., Balduyck, M., Bouchecareilh, M., Cuvelier, A., Epaud, R., Kerjouan, M., Le Rouzic, O., Pison, C., Plantier, L., Pujazon, M.-C., Reynaud-Gaubert, M., Toutain, A., Trumbic, B., Willemin, M.-C., Zysman, M., Brun, O., Campana, M., Chabot, F., Chamouard, V., Dechomet, M., Fauve, J., Girerd, B., Gnakamene, C., Lefrançois, S., Lombard, J.-N., Maitre, B., Maynié-François, C., Moerman, A., Payancé, A., Reix, P., Revel, D., Revel, M.-P., Schuers, M., Terrioux, P., Theron, D., Willersinn, F., Cottin, V., and Mal, H.

Published
2022
Full Text
View/download PDF

10. An innovative solution for breast cancer textual big data analysis

Author

Thiebaut, Nicolas, Simoulin, Antoine, Neuberger, Karl, Ibnouhsein, Issam, Bousquet, Nicolas, Reix, Nathalie, Molière, Sébastien, and Mathelin, Carole

Subjects
Statistics - Machine Learning, Computer Science - Computation and Language
Abstract

The digitalization of stored information in hospitals now allows for the exploitation of medical data in text format, as electronic health records (EHRs), initially gathered for other purposes than epidemiology. Manual search and analysis operations on such data become tedious. In recent years, the use of natural language processing (NLP) tools was highlighted to automatize the extraction of information contained in EHRs, structure it and perform statistical analysis on this structured information. The main difficulties with the existing approaches is the requirement of synonyms or ontology dictionaries, that are mostly available in English only and do not include local or custom notations. In this work, a team composed of oncologists as domain experts and data scientists develop a custom NLP-based system to process and structure textual clinical reports of patients suffering from breast cancer. The tool relies on the combination of standard text mining techniques and an advanced synonym detection method. It allows for a global analysis by retrieval of indicators such as medical history, tumor characteristics, therapeutic responses, recurrences and prognosis. The versatility of the method allows to obtain easily new indicators, thus opening up the way for retrospective studies with a substantial reduction of the amount of manual work. With no need for biomedical annotators or pre-defined ontologies, this language-agnostic method reached an good extraction accuracy for several concepts of interest, according to a comparison with a manually structured file, without requiring any existing corpus with local or new notations., Comment: In submission

Published
2017

13. Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Author

Keating, Claire, Yonker, Lael M, Vermeulen, François, Prais, Dario, Linnemann, Rachel W, Trimble, Aaron, Kotsimbos, Tom, Mermis, Joel, Braun, Andrew T, O'Carroll, Mark, Sutharsan, Sivagurunathan, Ramsey, Bonnie, Mall, Marcus A, Taylor-Cousar, Jennifer L, McKone, Edward F, Tullis, Elizabeth, Floreth, Tim, Michelson, Peter, Sosnay, Patrick R, Nair, Nitin, Zahigian, Rachel, Martin, Hannah, Ahluwalia, Neil, Lam, Anna, Horsley, Alexander, Krick, Stefanie, McCoy, Karen, Goss, Christopher, Weiner, Daniel, Billings, Joanne, Ren, Clement, Atkinson, Jeffrey, Linnemann, Rachel, Trimble, Aaron, Frederick, Carla, Liou, Theodore, Escobar, Hugo, Wang, Janice, Deschamps, Ashley, Froh, Deborah, Chmiel, James, Wurth, Mark, Yonker, Lael, Jain, Manu, Millard, Susan, Tolle, James, Filbrun, Amy, Taylor-Cousar, Jennifer, Ruiz, Fadel, Brown, Cynthia, Quick, Bryon, Brown, Perry, Kennedy, John, Ruddy, Jennifer, Shkolnik, Boris, Pancham, Krishna, DiMango, Emily, Fiel, Stanley, Mueller, Gary, Livingston, Floyd, Braun, Andrew, O'Sullivan, Brian, Dubin, Patricia, Teneback, Charlotte, Kremer, Ted, Welter, John, Hoppe, Jordana, Jain, Raksha, Calimano, Francisco, Johannes, Jimmy, Daines, Cori, Green, Deanna, Keens, Thomas, Trillo-Alvarez, Cesar, Scher, Herschel, Mermis, Joel, Morrissey, Brian, Wallace, James, Barrios, Christopher, Callison, John, Holliday, Zachary, Klingsberg, Ross, Efrati, Ori, Cohen-Cymberknoh, Malena, Prais, Dario, Azevedo, Pilar, Quintana-Gallego, Esther, Wong, Janice, Mondejar-Lopez, Pedro, Lopez Neyra, Alejandro, Amorim, Adelina, Sivam, Sheila, Asensio de la Cruz, Oscar, Waller, Michael, Forseen, Caralee, Marion, Chad, Dittrich, Anna-Maria, Lysinger, Jerimiah, Casserly, Brian, Luna, Carmen, Brown, Sarah, Singer, Jonathan, Schellhase, Dennis, Roberts, Jon, King, Christopher, Byrnes, Catherine, Ringshausen, Felix, Hebestreit, Helge, Lorenz, Michael, Ruppel, Renate, Drevinek, Pavel, Dillenhofer, Stefanie, Stahl, Mirjam, Gleiber, Wolfgang, Homola, Lukas, Naehrig, Susanne, Stehling, Florian, Sutharsan, Sivagurunathan, Fischer, Rainald, Poplawska, Krystyna, Haworth, Charles, Simmonds, Nicholas, Urquhart, Don, Duckers, Jamie, Carroll, Mary, Barry, Peter, Doe, Simon, Hilliard, Tom, MacGregor, Gordon, Patel, Neil, Withers, Nicholas, Peckham, Daniel, Ledson, Martin, Koser, Usma, Gartner, Silvia, Blitz Castro, Enrique, Sole Jover, Amparo, Cox, Desmond, McKone, Edward, Plant, Barry, Williamson, Michael, Elnazir, Basil, Barbosa, Telma, Cols Roig, Maria, Burr, Lucy, Henderson, Daniel, Middleton, Peter, Kotsimbos, Tom, De Monestrol, Isabelle, Gilljam, Marita, Lindberg, Ulrika, Schwarz, Carsten, Bode, Sebastian, Epton, Michael, Halasz, Adrien, Laki, Istvan, O'Carroll, Mark, Krick, Stefanie, McCoy, Karen, Goss, Christopher, Weiner, Daniel, Ren, Clement, Atkinson, Jeffrey, Linnemann, Rachel, Trimble, Aaron, Fortner, Christopher, Frederick, Carla, Liou, Theodore, Escobar, Hugo, Wang, Janice, Froh, Deborah, Chmiel, James, Wurth, Mark, Bilodeau, Lara, Lapey, Allen, Jain, Manu, Millard, Susan, Tolle, James, Moffett, Kathryn, Jia, Shijing, Taylor-Cousar, Jennifer, Brown, Cynthia, Brown, Perry, Uluer, Ahmet, Ruddy, Jennifer, Sears, Edmund, Pancham, Krishna, Keating, Claire, Fiel, Stanley, Mueller, Gary, Omlor, Gregory, Braun, Andrew, Mehdi, Nighat, Tupayachi Ortiz, Maria Gabriela, Teneback, Charlotte, Kremer, Ted, Messore, Barbara, Hoppe, Jordana, Jain, Raksha, Lambert, Allison, Mukadam, Zubin, Calimano, Francisco, Daines, Cori, Egan, Marie, Green, Deanna, Keens, Thomas, Wilhelm, Andrew, Morrissey, Brian, Reyes, Santiago, Schaeffer, David, Wallace, James, Callison, John, Klingsberg, Ross, Szepfalusi, Zsolt, Epaud, Ralph, Leroy, Sylvie, Fischer Biner, Reta, Moeller, Alexander, Salvatore, Donatello, Efrati, Ori, Cohen-Cymberknoh, Malena, Prais, Dario, Johnson, Larry, Wong, Janice, Gohy, Sophie, Gramegna, Andrea, Olesen, Hanne, Tissot, Adrien, Marguet, Christophe, Sivam, Sheila, Desai, Maya, Waller, Michael, Owens, Louisa, Kherani, Tamizan, Marion, Chad, Lysinger, Jerimiah, Sands, Dorota, Bakkeheim, Egil, Tullis, Elizabeth, Chilvers, Mark, Quon, Bradley, Lands, Larry, Parkins, Michael, Tremblay, Francois, Maitra, Anirban, Casserly, Brian, Staples, Heather, Elidemir, Okan, Chatziagorou, Elpis, Tirakitsoontorn, Pornchai, Grenet, Dominique, Brown, Sarah, Linnane, Barry, Nicholson, John Michael, Manika, Katerina, Tatopoulos, Aurelie, Byrnes, Catherine, Ruppel, Renate, Stahl, Mirjam, Pressler, Tacjana, Stehling, Florian, Sutharsan, Sivagurunathan, Bagheri-Potthoff, Azadeh, Fischer, Rainald, Haworth, Charles, Simmonds, Nicholas, Duckers, Jamie, Legg, Julian, Horsley, Alexander, MacGregor, Gordon, Peckham, Daniel, Lee, Timothy, Houdouin, Veronique, Ramel, Sophie, Fajac, Isabelle, Sermet-Gaudelus, Isabelle, Kamphuis, Lieke, van der Ent, Kors, Vermeulen, Francois, Chiron, Raphael, Reix, Philippe, Van Braeckel, Eva, Knoop, Christiane, Vanderhelst, Eef, Durieu, Isabelle, Bui, Stephanie, Weiss, Laurence, Le Rouzic, Olivier, van der Meer, Renske, Roukema, Jolt, Altenburg, Josje, Cox, Desmond, McKone, Edward, Plant, Barry, Williamson, Michael, Robinson, Philip, Wainwright, Claire, Burr, Lucy, Henderson, Daniel, Mulrennan, Siobhain, Clements, Barry, Middleton, Peter, Kotsimbos, Tom, Taccetti, Giovanni, Cipolli, Marco, Dacco, Valeria, Fabrizzi, Benedetta, Castellani, Carlo, Eber, Ernst, Appelt, Dorothea, Studnicka, Michael, De Monestrol, Isabelle, Gilljam, Marita, Sapiejka, Ewa, Mazurek, Henryk, Lindberg, Ulrika, Engan, Mette, Sauty, Alain, Mankikian, Julie, Epton, Michael, Halasz, Adrien, Laki, Istvan, and O'Carroll, Mark

Abstract

The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor–tezacaftor–deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor–tezacaftor–deutivacaftor compared with standard of care elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older.

Published
2025
Full Text
View/download PDF

14. Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Author

Hoppe, Jordana E, Kasi, Ajay S, Pittman, Jessica E, Jensen, Renee, Thia, Lena P, Robinson, Philip, Tirakitsoontorn, Pornchai, Ramsey, Bonnie, Mall, Marcus A, Taylor-Cousar, Jennifer L, McKone, Edward F, Tullis, Elizabeth, Salinas, Danieli B, Zhu, Jiaqiang, Chen, Yih-Chieh, Rodriguez-Romero, Violeta, Sosnay, Patrick R, Davies, Gwyneth, McPhail, Gary, McCoy, Karen, Roesch, Erica, Weiner, Daniel, Milla, Carlos, Pittman, Jessica, Linnemann, Rachel, Stone, Anne, Escobar, Hugo, Chmiel, James, Ruiz, Fadel, Gaffin, Jonathan, Levy, Hara, Lahiri, Thomas, Hoppe, Jordana, Moore, Brooke, Davies, Gwyneth, Moeller, Alexander, Dittrich, Anna-Maria, Latzin, Philipp, Tirakitsoontorn, Pornchai, Dowell, Maria, Thia, Lena, Stahl, Mirjam, Stehling, Florian, DeCelie-Germana, Joan, Sermet-Gaudelus, Isabelle, Janssens, Hettie, Reix, Philippe, Robinson, Philip, Wainwright, Claire, Tai, Andrew, and Svedberg, Marcus

Abstract

In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor–tezacaftor–deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 6–11 years.

Published
2025
Full Text
View/download PDF

15. Suivi des nourrissons exposés aux modulateurs de CFTR au cours de la grossesse

Author

Reix, Philippe, Audousset, Camille, Sermet Gaudelus, Isabelle, and Gautier, Sophie

Abstract

Le nombre de grossesses chez les femmes atteintes de mucoviscidose a considérablement augmenté au cours de ces dernières années, avec pour corollaire une hausse du nombre de fœtus sains exposés à la trithérapie par élexacaftor-tézacaftor-ivacaftor. Pour l’instant, les éléments concernant le devenir immédiat de ces enfants sont rassurants, mais des anomalies des tests hépatiques et des cas de cataracte ont été rapportés chez quelques nouveau-nés exposés in uteroet allaités. Sur le plus long terme, l’aspect neurodéveloppemental doit également être surveillé. Des recommandations d’un groupe de travail de la Société française de la mucoviscidose sont en cours d’élaboration pour le suivi de ces enfants au cours des deux premières années et au-delà.

Published
2025
Full Text
View/download PDF

16. Embolization of Persistent Type 2 Endoleaks After Endovascular Treatment of Abdominal Aortic Aneurysms: A Study of Long-Term Success

Author

Gallot, Marie, Roisin, Simon, Briffa, Florent, Chivot, Cyril, Meynier, Jonathan, Sevestre, Marie Antoinette, Reix, Thierry, and Soudet, Simon

Abstract

Endovascular treatment of abdominal aortic aneurysms (endovascular aneurysm repair [EVAR]) has been shown to be effective, with lower perioperative mortality and morbidity than open surgical treatment in patients with compatible anatomy. This benefit is lost after 3 years of follow-up. This could be explained by the higher rate of reintervention in EVAR patients due to endoleaks. Around half of patients with a persistent type 2 endoleak (T2EL) have an increase in aneurysm size. Either endovascular or conventional surgery techniques have been described to treat this type of endoleak. The aim of this study was to measure the long-term success rate of embolization of T2EL in a pragmatic retrospective series.

Published
2025
Full Text
View/download PDF

17. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.

Author

Burgel, Pierre-Régis, Sermet-Gaudelus, Isabelle, Girodon, Emmanuelle, Durieu, Isabelle, Houdouin, Véronique, Audousset, Camille, Macey, Julie, Grenet, Dominique, Porzio, Michele, Murris-Espin, Marlène, Reix, Philippe, Baravalle, Mélisande, Belleguic, Chantal, Mely, Laurent, Verhille, Juliette, Weiss, Laurence, Reynaud-Gaubert, Martine, Mittaine, Marie, Hamidfar, Rebecca, and Ramel, Sophie

Subjects
CYSTIC fibrosis, CYSTIC fibrosis transmembrane conductance regulator, LUNGS, CHLORIDES, PERCENTILES
Abstract

Elexacaftor–tezacaftor–ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with at least one of 177 rare variants. The aims of this study were to describe the clinical response to elexacaftor–tezacaftor–ivacaftor for people with cystic fibrosis without a F508del CFTR variant in France and to determine CFTR variant responsiveness to elexacaftor–tezacaftor–ivacaftor based on the observed clinical response. The French compassionate programme expanded access to elexacaftor–tezacaftor–ivacaftor to people with cystic fibrosis, aged 6 years and older, without a F508del variant, excluding those with two variants previously characterised as non-responsive. Participants at France's 47 cystic fibrosis centres were given a 4–6 week trial of elexacaftor–tezacaftor–ivacaftor and response was determined by a centralised committee based on evolution of clinical data, lung function, and sweat chloride concentration. Responsiveness of individual CFTR variants was derived from observed clinical responses. The first compassionnate programme was launched on May 19, 2022; by March 8, 2024, 516 people with cystic fibrosis had been identified for inclusion in this real-word study: 37 were not included due to the presence of two variants previously characterised as non-responsive to elexacaftor–tezacaftor–ivacaftor, and 479 (229 females [48%] and 250 males [52%]) received elexacaftor–tezacaftor–ivacaftor for 4–6 weeks. Among 443 participants who received no CFTR modulator before elexacaftor–tezacaftor–ivacaftor, 83 had at least one FDA-approved variant, of whom 81 (98%) were responders and continued elexacaftor–tezacaftor–ivacaftor; in responders, mean absolute change in sweat chloride was –44·5 mmol/L (95% CI –39·1 to –49·8) and percentage of predicted FEV 1 (ppFEV 1) was 11·1 percentage points (95% CI 8·4 to 13·7; both comparisons p<0·0001). Among 360 participants with no FDA-approved variant and no previous CFTR modulator, 177 (49%) were responders; in responders, mean absolute change in sweat chloride was –20·5 mmol/L (–17·2 to –23·8) and ppFEV 1 was 13·2 percentage points (11·4 to 15·0; both comparisons p<0·0001). Among 36 participants who were receiving ivacaftor before elexacaftor–tezacaftor–ivacaftor, 32 (89%) continued elexacaftor–tezacaftor–ivacaftor. Of 251 individual CFTR variants, 64 (28 FDA-approved) were classified as responsive or possibly responsive to elexacaftor–tezacaftor–ivacaftor, and 123 (two FDA-approved) as non-responsive or possibly non-responsive to elexacaftor–tezacaftor–ivacaftor. In France, over half of the population with cystic fibrosis without a F508del variant responded to elexacaftor–tezacaftor–ivacaftor, with most responders having no FDA-approved variant. The treatment period was relatively short and further research is warranted to describe the long-term safety and effectiveness of elexacaftor–tezacaftor–ivacaftor in this population. Association Vaincre la Mucoviscidose, Société Française de la Mucoviscidose, and Filière Maladies Rares MUCO-CFTR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. P118 Rare CFTR variants: knowing them to target them more successfully

Author

Chiron, R., primary, Coudrat, A., additional, Ronayette, A., additional, Sonnet, L., additional, Bareil, C., additional, Sasorith, S., additional, Abely, M., additional, Audousset, C., additional, Auffret, M., additional, Blondé, A., additional, Bluteau, C., additional, Bui, S., additional, Choubrac, C., additional, De Carli, P., additional, Delattre, C., additional, Dufeu, N., additional, Gueganton, L., additional, Hamidfar, R., additional, Ka, A., additional, Leroy, S., additional, Martin, C., additional, Mazur, S., additional, Orsero, S., additional, Pengam, J., additional, Quentin, J., additional, Ramel, S., additional, Raynal, C., additional, Reix, P., additional, Roussey-Bihouée, T., additional, Savadogo, M., additional, Tembely, D., additional, Thouvenin, G., additional, and Wizla, N., additional

Published
2024
Full Text
View/download PDF

21. P286 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis. Data from the French observational paediatric study MODUL-CF

Author

Weiss, L., primary, Galderisi, A., additional, Besançon, A., additional, Stremler, N., additional, Reix, P., additional, Wizla, N., additional, Rames, C., additional, Marguet, C., additional, Tatapoulos, A., additional, Perrisson, C., additional, Dalphin, M.-L., additional, Troussier, F., additional, Houdouin, V., additional, Abely, M., additional, Cosson, L., additional, Gabsi, A., additional, Corvol, H., additional, Deneuville, E., additional, Storni, V., additional, Ramel, S., additional, Bui, S., additional, Heraud, M.-C., additional, Epaud, R., additional, Huet, F., additional, Scalbert, M., additional, Mely, L., additional, Gachelin, E., additional, Giannantonio, M., additional, Sahki, D., additional, Lustre, A., additional, Bonnel, A.-S., additional, and Sermet, I., additional

Published
2024
Full Text
View/download PDF

25. Retrospective Cohort Study on EVAR Open Surgical Conversion: Focus on Endoleaks With Wrong Preoperative Categorization

Author

Roisin, Simon, Simon, Soudet, Adriane, Mage, and Thierry, Reix

Abstract

Late open conversion (LOC) following endovascular aneurysm repair (EVAR) is a rare complication with a high morbidity and mortality and is often proposed as the last line of treatment after failure of endovascular reintervention of any type. This study aimed to highlights the limitations of EVAR follow-up imaging in characterizing endoleaks, which may contribute to the failure of endovascular reinterventions and lead to LOC.

Published
2024
Full Text
View/download PDF

26. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTRvariant: a real-world study

Author

Burgel, Pierre-Régis, Sermet-Gaudelus, Isabelle, Girodon, Emmanuelle, Durieu, Isabelle, Houdouin, Véronique, Audousset, Camille, Macey, Julie, Grenet, Dominique, Porzio, Michele, Murris-Espin, Marlène, Reix, Philippe, Baravalle, Mélisande, Belleguic, Chantal, Mely, Laurent, Verhille, Juliette, Weiss, Laurence, Reynaud-Gaubert, Martine, Mittaine, Marie, Hamidfar, Rebecca, Ramel, Sophie, Cosson, Laure, Douvry, Benoit, Danner-Boucher, Isabelle, Foucaud, Pierre, Roy, Charlotte, Burnet, Espérie, Raynal, Caroline, Audrezet, Marie-Pierre, Da Silva, Jennifer, Martin, Clémence, Kanaan, Reem, Carlier, Nicolas, Honoré, Isabelle, Chedevergne, Frédérique, Dreano, Elise, Hatton, Aurélie, Hinzpeter, Alexandre, Pranke, Iwona, Le Clainche-Viala, Laurence, Mayer, Sophie, Corvol, Harriet, Thouvenin, Guillaume, de Miranda, Sandra, Remus, Natascha, Douvry, Benoit, Duthoit, Louise, Perez, Thierry, Le Rouzic, Olivier, Wizla, Nathalie, Bon, Claire, Bui, Stéphanie, Poey, Nora, Stremler, Nathalie, Coltey, Bérengère, Dufeu, Nadine, Lebihan, Jean, Gabsi, Asma, Pouradier, Delphine, Andrejak, Claire, Rames, Cinthia, Dupuy-Grasset, Magali, Languepin, Jeanne, Marguet, Christophe, Pramil, Stéphanie, Arnouat, Baptiste, Fanton, Annlyse, Abely, Michel, Ravoninjatovo, Bruno, Blondé, Aurore, Guillaumot, Anne, Kieffer, Sebastien, Tatopoulos, Aurélie, Nove-Josserand, Raphaële, Ohlmann, Camille, Perrin, Thomas, Reynaud, Quitterie, Llerena, Catherine, Quétant, Sébastien, Valois, Sophie, Dalphin, Marie-Laure, Richaud-Thiriez, Bénédicte, Deneuville, Eric, Chiron, Raphael, Socchi, Floriane, Bihouée, Tiphaine, Mankikian, Julie, Flament, Thomas, Coolen-Allou, Nathalie, Gachelin, Elsa, Périsson, Caroline, Vuillard, Constance, Dupuis, Marion, Alkoussa, Wael, Marchal, Sarah, Leroy, Sylvie, Scalbert, Manuela, Campbell, Karine, Laurans, Muriel, Labbé, Guillaume, Montcouquiol, Sylvie, Priou, Pascaline, de Carli, Paola, Lemonnier, Lydie, Dehillotte, Clémence, and Nouvel, Thierry

Abstract

Elexacaftor–tezacaftor–ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTRvariant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with at least one of 177 rare variants. The aims of this study were to describe the clinical response to elexacaftor–tezacaftor–ivacaftor for people with cystic fibrosis without a F508del CFTRvariant in France and to determine CFTRvariant responsiveness to elexacaftor–tezacaftor–ivacaftor based on the observed clinical response.

Published
2024
Full Text
View/download PDF

28. Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data

Author

Rouzé H, Viprey M, Allemann S, Dima AL, Caillet P, Denis A, Poupon-Bourdy S, Camara B, Llerena C, Reix P, Durieu I, Reynaud Q, and Touzet S

Subjects
cystic fibrosis, chronic treatment, medication adherence, administrative claims data, prescription data, Medicine (General), R5-920
Abstract

Héloïse Rouzé1,2, Marie Viprey1,2, Samuel Allemann2, Alexandra L Dima2, Pascal Caillet3, Angélique Denis1, Stéphanie Poupon-Bourdy1, Boubou Camara4, Catherine Llerena5, Philippe Reix6, Isabelle Durieu2,7, Quitterie Reynaud2,7, Sandrine Touzet1,2 1Public Health Department, Hospices Civils de Lyon, Lyon, France; 2HESPER Lab-EA 7425, Université de Lyon-Université Claude Bernard Lyon 1, Lyon, France; 3Department of Clinical Pharmacology, CHU de Nantes, Nantes, France; 4Pulmonary Department, Adult CF Center, CHU de Grenoble, Grenoble, France; 5Pediatric Pulmonology Department, Pediatric CF Center, CHU de Grenoble, Grenoble, France; 6Pediatric Pulmonology Department, Pediatric CF Center, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Lyon, France; 7Department of Internal Medicine, Adult Cystic Fibrosis Care Center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, FranceCorrespondence: Héloïse RouzéHospices Civils de Lyon, Pôle de Santé Publique, Bâtiment A, 6ème étage, 162 Avenue Lacassagne 69003 Lyon, FranceTel +33 47 211 5132Email heloise.rouze@chu-lyon.frBackground: Cystic fibrosis (CF) is a life-shortening genetic condition that usually affects several organs and involves significant treatment burden. Adherence to medication is important for successful CF management.Objective: To describe medication adherence according to age, therapeutic class, and pharmaceutical form in adults and children followed in four regional CF centers in France.Methods: We conducted a cross-sectional study with non-transplanted patients followed in two adult and two pediatric centers during 2015 who were covered by the French National Health Insurance (NHI). Sociodemographic, clinical, hospitalization, and prescription data were collected from patient medical records. Medication dispensations were extracted from the regional French NHI database. Adherence was calculated over 12 months using continuous medication availability (CMA) accounting for dose adjustments and hospitalizations. Drug-specific CMA was computed in R with the AdhereR package for each medication prescribed more than 3 months, which was averaged to obtain a composite CMA score (cCMA) for all treatments and per therapeutic class as well as pharmaceutical form for each patient.Results: A total of 228 patients were included. The number of chronic medications increased with age (r=0.50, p

Published
2019

29. Les soins palliatifs au Liban, un essor freiné mais une résilience à toute épreuve

Author

El Khoury, Joe and Reix, Fanny

Abstract

L’histoire des soins palliatifs au Liban est marquée par la résilience et la persévérance. Portés par des initiatives personnelles, des combats législatifs et des donations privées, les soins palliatifs ont réussi à s’ancrer petit à petit dans le paysage médical, malgré les maigres moyens proposés par l’État. La délivrance des soins palliatifs au Liban a la particularité d’être soutenue principalement par des ONG à but non lucratif, dont le fonctionnement est à mi-chemin entre HAD et EMSP françaises et qui offrent des soins gratuits aux patients. Plus de 30 % des patients suivis par l’ONG BALSAM souffrent de maladies chroniques non cancéreuses. Les soins palliatifs pédiatriques sont quasi-inexistants, BALSAM étant la seule ONG assurant un accompagnement des enfants à leur domicile. Face aux difficultés financières majeures que connaît le pays, ces ONG se tournent aujourd’hui vers des partenariats internationaux, à la fois pour s’assurer les moyens de poursuivre leurs missions, et pour se réserver une place sur la scène mondiale. Le modèle libanais développé par BALSAM est présenté dans les pays en voie de développement comme un exemple possible de fonctionnement en contexte de crise. Une délégation du centre médicochirurgical de réadaptation des massues (CMCR) à Lyon est par ailleurs intervenue au centre hospitalier Rafik Hariri de Beyrouth pour échanger sur trois thématiques : management, rééducation et soins palliatifs. Les mêmes difficultés que nous rencontrons en France concernant la temporalité d’intervention dans une prise en charge ont pu être relevées : il est peu courant pour les confrères médecins libanais de solliciter les soins palliatifs précocement. La place des soins palliatifs au sein de l’institution hospitalière est encore nouvelle, et les moyens alloués trop faibles, autant en temps soignants qu’en locaux adaptés. La route reste longue, mais tout est mis en œuvre pour que les soins palliatifs continuent de faire parler d’eux et de s’étendre toujours plus profondément au sein du système sanitaire libanais.

Published
2024
Full Text
View/download PDF

37. Diffuse alveolar haemorrhage in children: an international multicentre study

Author

Ring, A.M. Schwerk, N. Kiper, N. Aslan, A.T. Aurora, P. Ayats, R. Azevedo, I. Bandeira, T. Carlens, J. Castillo-Corullon, S. Cobanoglu, N. Elnazir, B. Emiralioğlu, N. Eyuboglu, T.S. Fayon, M. Gursoy, T.R. Hogg, C. Kötz, K. Karadag, B. Látalová, V. Krenke, K. Lange, J. Manali, E.D. Osona, B. Papiris, S. Proesmann, M. Reix, P. Roditis, L. Rubak, S. Rumman, N. Snijders, D. Stehling, F. Weiss, L. Yalcın, E. Zirek, F. Bush, A. Clement, A. Griese, M. Buchvald, F.F. Nathan, N. Nielsen, K.G. and Ring, A.M. Schwerk, N. Kiper, N. Aslan, A.T. Aurora, P. Ayats, R. Azevedo, I. Bandeira, T. Carlens, J. Castillo-Corullon, S. Cobanoglu, N. Elnazir, B. Emiralioğlu, N. Eyuboglu, T.S. Fayon, M. Gursoy, T.R. Hogg, C. Kötz, K. Karadag, B. Látalová, V. Krenke, K. Lange, J. Manali, E.D. Osona, B. Papiris, S. Proesmann, M. Reix, P. Roditis, L. Rubak, S. Rumman, N. Snijders, D. Stehling, F. Weiss, L. Yalcın, E. Zirek, F. Bush, A. Clement, A. Griese, M. Buchvald, F.F. Nathan, N. Nielsen, K.G.

Abstract

Background Paediatric diffuse alveolar haemorrhage (DAH) is a rare heterogeneous condition with limited knowledge on clinical presentation, treatment and outcome. Methods A retrospective, descriptive multicentre follow-up study initiated from the European network for translational research in children’s and adult interstitial lung disease (Cost Action CA16125) and chILD-EU CRC (the European Research Collaboration for Children’s Interstitial Lung Disease). Inclusion criteria were DAH of any cause diagnosed before the age of 18 years. Results Data of 124 patients from 26 centres (15 counties) were submitted, of whom 117 patients fulfilled the inclusion criteria. Diagnoses were idiopathic pulmonary haemosiderosis (n=35), DAH associated with autoimmune features (n=20), systemic and collagen disorders (n=18), immuno-allergic conditions (n=10), other childhood interstitial lung diseases (chILD) (n=5), autoinflammatory diseases (n=3), DAH secondary to other conditions (n=21) and nonspecified DAH (n=5). Median (IQR) age at onset was 5 (2.0–12.9) years. Most frequent clinical presentations were anaemia (87%), haemoptysis (42%), dyspnoea (35%) and cough (32%). Respiratory symptoms were absent in 23%. The most frequent medical treatment was systemic corticosteroids (93%), hydroxychloroquine (35%) and azathioprine (27%). Overall mortality was 13%. Long-term data demonstrated persistent abnormal radiology and a limited improvement in lung function. Conclusions Paediatric DAH is highly heterogeneous regarding underlying causes and clinical presentation. The high mortality rate and number of patients with ongoing treatment years after onset of disease underline that DAH is a severe and often chronic condition. This large international study paves the way for further prospective clinical trials that will in the long term allow evidence-based treatment and follow-up recommendations to be determined. © The authors 2023.

Published
2023

38. P086 The French clinical research network in cystic fibrosis more than 10 years of positive experience in clinical research for patients

Author

Coudrat, A., primary, Auffret, M., additional, Chiron, R., additional, Abely, M., additional, Bluteau, C., additional, Bui, S., additional, Choubrac, C., additional, Carli, P. De, additional, Delattre, C., additional, Dufeu, N., additional, Epaud, R., additional, Rouzic, O. Le, additional, Mazur, S., additional, Orsero, S., additional, Pengam, J., additional, Ramel, S., additional, Reix, P., additional, Savadogo, M., additional, Wizla, N., additional, Gueganton, L., additional, and Ronayette, A., additional

Published
2023
Full Text
View/download PDF

43. Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study

Author

Fumery, Mathurin, Kohut, Mathieu, Gower-Rousseau, Corinne, Duhamel, Alain, Brazier, Franck, Thelu, Francoise, Nagorniewicz, Francis, Lamarche, Francois, Nguyen-Khac, Eric, Sabbagh, Charles, Loreau, Julien, Colombel, Jean-Frederic, Savoye, Guillaume, Chatelain, Denis, Dupas, Jean-Louis, Bartoli, E., Bental, A., Brazier, F., Butel, J., Capron-Chivrac, D., Coevoet, H., Cohen, G., Dadamessi, I., Delcenserie, R., Delgrange, T., Descombes, P., Dupas, J. L., Heyman, B., Joly, J. P., Lagarde, M., Laude, D., Mancheron, H., Nguyen-Khac, E., Papazian, A., Pauwels, B., Pauwels, M., Prevost, J. C., Reix-Branche, N., Rudelli, A., Sevenet, F., Triplet, C., Wantiez, M., On behalf on the Somme MC group, and EPIMAD group

Published
2017
Full Text
View/download PDF

44. Pulmonary hemosiderosis in children with Down syndrome: a national experience

Author

Alimi, Aurelia, Taytard, Jessica, Abou Taam, Rola, Houdouin, Véronique, Forgeron, Aude, Lubrano Lavadera, Marc, Cros, Pierrick, Gibertini, Isabelle, Derelle, Jocelyne, Deschildre, Antoine, Thumerelle, Caroline, Epaud, Ralph, Reix, Philippe, Fayon, Michael, Roullaud, Sylvie, Troussier, Françoise, Renoux, Marie-Catherine, de Blic, Jacques, Leyronnas, Sophie, Thouvenin, Guillaume, Perisson, Caroline, Ravel, Aimé, Clement, Annick, Corvol, Harriet, Nathan, Nadia, and for the French RespiRare® group

Published
2018
Full Text
View/download PDF

45. Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort

Author

Fletcher, Camille, Hadchouel, Alice, Thumerelle, Caroline, Mazenq, Julie, Fleury, Manon, Corvol, Harriet, Jedidi, Nouha, Benhamida, Myriam, Bessaci, Katia, Bilhouee, Tiphaine, Borie, Raphael, Brouard, Jacques, Cantais, Aurélie, Clement, Annick, Coutier, Laurianne, Cisterne, Camille, Cros, Pierrick, Dalphin, Marie-Laure, Delacourt, Christophe, Deneuville, Eric, Dubus, Jean-Christophe, Egron, Carole, Epaud, Ralph, Fayon, Michael, Forgeron, Aude, Gachelin, Elsa, Galode, Francois, Gertini, Isabelle, Giovannini-Chami, Lisa, Gourdan, Pierre, Guiddir, Tamazoust, Herzog, Audrey, Houdouin, Véronique, Hullo, Églantine, Jarreau, Pierre-Henri, Labbé, Guillame, Labouret, Géraldine, Ladaurade, Alice, Le Clainche Viala, Laurence, Marguet, Christophe, Masson-Rouchaud, Alexandra, Perisson, Caroline, Rames, Cinthia, Reix, Philippe, Renoux, Marie-Catherine, Roditis, Léa, Schweitzer, Cyril, Tatopoulos, Aurélie, Trioche-Eberschweiler, Pascale, Troussier, Francoise, Vigier, Clémentine, Weiss, Laurence, Legendre, Marie, Louvrier, Camille, de Becdelievre, Alix, Coulomb, Aurore, Sileo, Chiara, Ducou le Pointe, Hubert, Berteloot, Laureline, Delestrain, Céline, and Nathan, Nadia

Abstract

IntroductionInterstitial lung disease in children (chILD) are rare and mostly severe lung diseases. Very few epidemiological data are available in limited series of patients. The aim of this study was to assess the prevalence and incidence of chILD in France.MethodsWe performed within the RespiRare network a multicentre retrospective observational study in patients with chILD from 2000 to 2022 and a prospective evaluation of chILD’s incidence between February 2022 and 2023.ResultschILD was reported in 790 patients in 42 centres. The estimated 2022 prevalence in France was 44 /million children (95% CI 40.76 to 47.46) and the computed incidence was 4.4 /million children (95% CI 3.44 to 5.56). The median age at diagnosis was 3 months with 16.9% of familial forms. Lung biopsy and genetic analyses were performed in 23.4% and 76.9%, respectively. The most frequent chILD aetiologies in the <2 years group were surfactant metabolism disorders (16.3%) and neuroendocrine cell hyperplasia of infancy (11.8%), and in the 2–18 years group diffuse alveolar haemorrhage (12.2%), connective tissue diseases (11.4%), hypersensitivity pneumonitis (8.8%) and sarcoidosis (8.8%). The management included mainly oxygen therapy (52%), corticosteroid pulses (56%), oral corticosteroids (44%), azithromycin (27.2%), enteral nutrition (26.9%), immunosuppressants (20.3%) and hydroxychloroquine (15.9%). The 5-year survival rate was 57.3% for the patients diagnosed before 2 years and 86% between 2 and 18 years.ConclusionThis large and systematic epidemiological study confirms a higher incidence and prevalence of chILD than previously described. In order to develop international studies, efforts are still needed to optimise the case collection and to harmonise diagnostic and management practices.

Published
2024
Full Text
View/download PDF

46. Late-onset pulmonary complications following allogeneic hematopoietic cell transplantation in pediatric patients: a prospective multicenter study

Author

Houdouin, Véronique, Dubus, Jean Christophe, Crepon, Sophie Guilmin, Rialland, Fanny, Bruno, Bénedicte, Jubert, Charlotte, Reix, Philippe, Pasquet, Marlène, Paillard, Catherine, Adjaoud, Dalila, Schweitzer, Cyril, Le Bourgeois, Muriel, Pages, Justine, Yacoubi, Adyla, Dalle, Jean Hugues, Bergeron, Anne, and Delclaux, Christophe

Abstract

The primary objective of our multicenter prospective study was to describe the incidence of late-onset non-infectious pulmonary complications (LONIPCs) in children undergoing hematopoietic cell transplantation (HCT) using sensitive criteria for pulmonary function test (PFT) abnormalities including the non-specific pattern of airflow obstruction. Secondary objectives were to assess the factors associated with LONIPC occurrence and the sensitivity of the 2014 NIH-Consensus Criteria of bronchiolitis obliterans syndrome (BOS). PFT and clinical assessment were performed prior to HCT and at 6, 12, 24, and 36 months post-HCT. LONIPC diagnosis was validated by an Adjudication Committee. The study comprised 292 children from 12 centers. Thirty-two individuals (11%, 95% CI: 8–15%) experienced 35 LONIPCs: 25 BOS, 4 interstitial lung diseases, 4 organizing pneumonia and 2 pulmonary veno-occlusive diseases. PFT abnormalities were obstructive defects (FEV1/FVC z-score < −1.645; n= 12), restrictive defects (TLC < 80% predicted, FEV1and FVC z-scores < −1.645; n= 7) and non-specific pattern (FEV1and FVC z-score< −1.645, FEV1/FVC z-score > −1.645, and TLC > 80% predicted; n= 8). HCT for malignant disease was the only factor associated with LONIPC (P= 0.04). The 2014 NIH-Consensus Criteria would only diagnose 8/25 participants (32%) as having BOS. In conclusion, 11% of children experienced a LONIPC in a prospective design. Clinical Trials.gov identifier (NCT number): NCT02032381.

Published
2024
Full Text
View/download PDF

48. Clinical Presentation, Diagnosis, and Bacterial Epidemiology of Peritoneal Tuberculosis in Two University Hospitals in France

Author

Cavalli, Zoé, Ader, Florence, Valour, Florent, Saison, Julien, Boussel, Loïc, Dumitrescu, Oana, Perpoint, Thomas, Chidiac, Christian, May, Thierry, Ferry, Tristan, Adelaïde, L., Ader, F., Biron, F., Boibieux, A., Bouaziz, A., Bouledrak, K., Braun, E., Broussolle, C., Carret, G., Catho, G., Charhon, N., Chidiac, C., Chumbi-Flores, W., Coppere, B., Couraud, S., Demontclos, M., Devouassoux, G., Dumitrescu, O., Ernesto, S., Ferry, T., Floret, D., Fredenucci, I., Freymond, N., Gardes, S., Gerbier-Colomban, S., Gillet, Y., Girard-Madoux, M. H., Goutelle, S., Grando, J., Grima, R., Hees, L., Hodille, E., Hot, A., Karsenty, J., Kiakouama-Maleka, L., Lina, G., Maury, J. M., Miailhes, P., Moreau, L., Nesme, P., Ninet, J., Perard, L., Perpoint, T., Perrot, E., Ranc, A. G., Rasigade, J. P., Reix, R., Renaud-Baron, A. S., Saison, J., Senechal, A., Sève, P., Souquet, P. J., van Thai, H., Tronc, F., Valour, F., Vanhems, P., and Lyon TB Study group

Published
2016
Full Text
View/download PDF

49. Allergen sensitization patterns in the French COBRAPed cohort

Author

Lejeune, S, Bouazza, N, Roland Nicaise, P, Jolaine, V, Roditis, L, Marguet, C, Houdoin, V, Berger, P, Fayon, M, Dubus, J, Pin, I, Reix, P, Pellan, M, Brouard, J, Chiron, R, Giovannini-Chami, L, de Blic, J, Deschildre, A, Lezmi, G, Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Pneumologie et allergologie pédiatriques [CHU Jeanne de Flandre, Lille], Hôpital Jeanne de Flandre [Lille], Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] (FHU ACRONIM), CHU Bordeaux [Bordeaux], Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU), Hôpital de la Timone [CHU - APHM] (TIMONE), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Département de Pédiatrie - CHRU de Grenoble, CHU Grenoble, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Burgundy School of Business (BSB) - Ecole Supérieure de Commerce de Dijon Bourgogne (ESC) (BSB), Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Hôpitaux Pédiatriques de Nice Lenval (CHU-Lenval), Centre Hospitalier Universitaire de Nice (CHU Nice), Université de Nice Sophia-Antipolis (UNSA), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Service de Pneumologie et d'Allergologie Pédiatriques

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience

Published
2022
Full Text
View/download PDF

50. The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery

Author

Bigot, Pierre, Bernhard, Jean-Christophe, Gill, Inderbir S., Vuong, Nam Son, Verhoest, Grégory, Flamand, Vincent, Reix, Boris, Suer, Evren, Gökce, Ilker, Beauval, Jean Baptiste, Nouhaud, François Xavier, Eto, Masatoshi, Baco, Eduard, Matsugasumi, Toru, Chowaniec, Yvonne, Rigaud, Jérôme, Lenormand, Claire, Pfister, Christian, Hetet, Jean François, Ploussard, Guillaume, Roupret, Morgan, Léon, Priscilla, Bakri, Adnan El, Larré, Stéphane, Tillou, Xavier, Doerfler, Arnaud, Descazeaud, Aurélien, Koutlidis, Nicolas, Schneider, Alexandre, Sebe, Philippe, Ingels, Alexandre, Azzouzi, Abdel Rahmène, Soulié, Michel, Méjean, Arnaud, Bensalah, Karim, Patard, Jean-Jacques, and the members of the Kidney Cancer group of the CCAFU

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results